Full Breakdown
Genetic Ancestry Influences Acral Melanoma Biology and Treatment Outcomes
2/19/2026, 11:24:35 AM
Understanding Acral Melanoma
Acral melanoma, a rare and aggressive subtype of skin cancer, has been found to exhibit significant variations in its biological behavior based on genetic ancestry. Researchers from the Wellcome Sanger Institute and the National Autonomous University of Mexico (UNAM) conducted a comprehensive study analyzing the genetic makeup of 123 acral melanoma tumors from 92 Mexican patients. Their findings, published in *Nature*, underscore the importance of including diverse populations in cancer research to enhance understanding and treatment of this disease.
Genetic Variability and Patient Outcomes
The study revealed that acral melanoma differs markedly from other melanoma types, which are primarily linked to ultraviolet (UV) radiation exposure. While typical melanomas are prevalent in populations of European descent, acral melanoma predominantly affects individuals with Indigenous American, Asian, and African ancestries. The researchers identified three distinct clusters of acral melanoma tumors, each associated with different clinical outcomes:
1. Immune-Related Gene Expression: Tumors with higher levels of immune-related gene activity were linked to better patient outcomes.
2. Rapid Cell Growth and Pigmentation: Tumors characterized by rapid growth and pigmentation pathways were associated with recurrence and poorer prognoses.
3. Metabolic Pathway Changes: A third group exhibited altered metabolic pathways, leading to variable outcomes.
Notably, classic melanoma mutations, such as those in the BRAF gene, were less common in this cohort, with European ancestry correlating with a higher likelihood of BRAF mutations compared to Indigenous American ancestry.
Implications for Cancer Research and Treatment
The findings highlight a critical gap in cancer genomics, particularly the underrepresentation of non-European populations in research. Dr. Patricia Basurto-Lozada, the study's first author, emphasized that acral melanoma is not a monolithic disease but rather consists of distinct biological groups that necessitate tailored treatment approaches. This research advocates for the inclusion of diverse ancestral backgrounds in clinical trials to improve treatment efficacy and patient outcomes.
Dr. Carla Daniela Robles-Espinoza, a senior author of the study, noted the importance of understanding genetic diversity in treatment responses, stating, "When patients enter clinical trials, it is not a one-size-fits-all approach." This sentiment echoes the broader call for more inclusive research practices to address the unique challenges posed by rare cancers like acral melanoma.
Criticism and Future Directions
Despite the study's contributions, there remains a concern regarding the limited cancer registries in Latin America, which hampers the ability to track cancer trends effectively. Dr. Patrícia Abrão Possik, co-author and Group Leader at the Brazilian National Cancer Institute, highlighted this issue, indicating that improved data collection is essential for advancing cancer research in the region.
Verbatim Quotes
- “We found that acral melanoma is not a single disease. Tumors fall into distinct biological groups that are linked to different patient outcomes. This information may be crucial for developing targeted treatments for acral melanoma in the future and ultimately improving the lives of patients.” — Dr. Patricia Basurto-Lozada, National Autonomous University of Mexico
- “To understand how well treatments work, we need studies that include people from diverse ancestral backgrounds.” — Dr. Carla Daniela Robles-Espinoza, Wellcome Sanger Institute
- “David Adams, co-senior author at the Wellcome Sanger Institute, observed, "Our research highlights the underrepresented nature of cancer genomics studies.” — Dr. David Adams, Wellcome Sanger Institute
The study's insights into the genetic underpinnings of acral melanoma pave the way for more personalized treatment strategies, ultimately aiming to improve the lives of patients affected by this aggressive cancer.
